Evidence map›Paper›PMID 21526899›Full record

ReviewFuture medicinal chemistry2011

The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis.

Laura A Solt, Douglas J Kojetin, Thomas P Burris

Open access · greenAbstract readReview
In one paragraph

Review in Future medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 185 citations in OpenAlex.

  1. Review
  2. Review
  3. bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. The Circadian Modulators as Molecular Targets in Cancer-A Review.International journal of molecular sciences · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Laura A SoltThe Scripps Research Institute, Jupiter, FL 33458, USA.
Douglas J Kojetin
Thomas P Burris
Scripps Research Institute · US

Funding

Development of ROR ligands for treatment of circadian rhythm disordersR01MH092769 · NIMH · ST. LOUIS COLLEGE OF PHARMACY · PI BURRIS, THOMAS P, WALKER, JOHN K. · 2011 to 2020
$6.1M
Regulation of REV-ERBalpha and REV-ERBbeta function of HEMER01DK080201 · NIDDK · SCRIPPS RESEARCH INSTITUTE, THE · PI BURRIS, THOMAS P · 2008 to 2012
$1.9M
Development of ROR ligands for treatment of metabolic diseasesR24DK089984 · NIDDK · SCRIPPS RESEARCH INSTITUTE, THE · PI BURRIS, THOMAS P · 2010 to 2010
$583k
Investigating the Mechanisms Regulating RORgamma ActivityF32DK088499 · NIDDK · SCRIPPS RESEARCH INSTITUTE, THE · PI SOLT, LAURA A · 2010 to 2013
$124k
NIDDK NIH HHS DK080201NIDDK NIH HHS DK088499NIDDK NIH HHS DK089984NIDDK NIH HHS F32 DK088499NIDDK NIH HHS R01 DK080201NIDDK NIH HHS R24 DK089984NIMH NIH HHS MH092769NIMH NIH HHS R01 MH092769
6 · The paper itself

Abstract

Research efforts spanning the past two decades have established a clear link between nuclear receptor function, regulation of the circadian clock and lipid homeostasis. As such, this family of receptors represents an important area of research. Recent advances in the field have identified two nuclear receptor subfamilies, the REV-ERBs and the 'retinoic acid receptor-related orphan receptors' (RORs), as critical regulators of the circadian clock with significant roles in lipid homeostasis. In this review, the latest information garnered from cutting-edge research on these two nuclear receptor subfamilies will be discussed. Through direct targeting of the REV-ERBs and RORs with synthetic ligands, generation of novel tools aimed at characterizing their function in vivo have been developed, which may lead to novel therapeutics for the treatment of metabolic disorders.

Indexed as

Circadian RhythmLipid MetabolismAnimalsCircadian Rhythm Signaling Peptides and ProteinsHumansLigandsMetabolic DiseasesModels, MolecularNuclear Receptor Subfamily 1, Group D, Member 1Nuclear Receptor Subfamily 1, Group F, Member 1Nuclear Receptor Subfamily 1, Group F, Member 2Orphan Nuclear ReceptorsCircadian Rhythm Signaling Peptides and ProteinsLigandsNuclear Receptor Subfamily 1, Group D, Member 1Nuclear Receptor Subfamily 1, Group F, Member 1Nuclear Receptor Subfamily 1, Group F, Member 2Orphan Nuclear Receptors

Identifiers

PMID21526899
PMCPMC3134326
OpenAlexW1972571170

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.